MBX Biosciences Previews Phase 2 Data for Once-Weekly Canvuparatide Ahead of ENDO 2026
Event summary
- MBX Biosciences to host investor event June 12, 2026 to discuss Phase 2 trial results for once-weekly canvuparatide.
- One-year open-label extension data and full 12-week AvailTM Phase 2 trial results to be presented at ENDO 2026.
- Presentations scheduled for June 12 and June 13, 2026 during the Endocrine Society’s Annual Meeting in Chicago.
- Key participants include Richard DiMarchi, Ph.D. (Indiana University) and Michael T. Collins, M.D. (NIH).
The big picture
MBX Biosciences is positioning itself as a key player in the treatment of endocrine and metabolic disorders with its proprietary PEP™ platform. The upcoming data presentations at ENDO 2026 are critical for validating the company's once-weekly canvuparatide formulation, which could differentiate it in the competitive landscape of chronic hypoparathyroidism treatments. The strategic involvement of academic and NIH experts underscores the scientific rigor behind the development.
What we're watching
- Clinical Efficacy
- How the Phase 2 data for once-weekly canvuparatide will position MBX Biosciences in the chronic hypoparathyroidism market.
- Regulatory Pathway
- Whether the positive trial results will accelerate the transition to Phase 3 development for canvuparatide.
- Market Differentiation
- The pace at which MBX Biosciences can establish canvuparatide as a leading treatment option in its therapeutic category.
Related topics